Abstract Search Browse Program and Abstracts Schedule-at-a-Glance Conference Mission & Sponsors Program Committee Contact Us


58. Slide Session
Antibodies and Cytokines
Moderators: Peter Wright, Vanderbilt Univ. Med. Ctr., Nashville, TN, USA and Susan Zolla-Pazner, New York Univ. Sch. of Med., NY, USA

Abstracts

#Title
313 Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41
M. B. Zwick1, M. Wang1, C. Spenlehauer2, J. M. Binley1, J. P. Moore2, G. Stiegler3, H. Katinger2, D. R. Burton1, and P. W. H. I. Parren1*
1The Scripps Res. Inst., La Jolla, CA, USA; 2Cornell Univ., New York, NY, USA; and 3Inst. for Applied Microbiology, Univ. of Agriculture, Vienna, Austria
314 Enhanced Vaccine Technologies for the Induction of Potent Neutralizing Antibodies and Cellular Immune Responses against HIV
S. W. Barnett*1, I. K. Srivastava1, L. Stamatatos2, D. Montefiori3, S. Engelbrecht4, E. Janse Van Rensburg4, G. R. Otten1, D. O'Hagan1, J. Polo1, J. B. Ulmer1, and J. J. Donnelly1
1Chiron Corp., Emeryville, CA, USA; 2The Aaron Diamond AIDS Res. Ctr., New York, NY, USA; 3Duke Univ., Durham, NC, USA; and 4Univ. of Stellenbosch and Tygerberg Hosp., South Africa
315 Human Monoclonal Antibodies (mAbs) Generated from Cells of Clade A-Infected Individuals
S. Zolla-Pazner*1,2, B. Volsky1, C. Williams1, K. Revesz2, S. Cohen1, P. Nyambi1, W. J. Honnen3, C. Krachmarov3, A. Pinter3, and M. K. Gorny1
1New York Univ. Sch. of Med., USA; 2Veterans Affairs Med. Ctr., New York, NY, USA; and 3Publ. Hlth. Res. Inst., New York, NY, USA
316 HIV Neutralizing Antibodies in Seronegative Volunteers in a Phase I/II Prime-Boost Vaccine Trial in Thailand
V. Polonis*1, J. Kim1, S. Nittayaphan2, P. Pittisuttithum3, R. El Habib4, W. Heyward5, A. Brown2, J. McNeil1, D. Birx1, and the TAVEG6
1The US Military HIV Res. Prgm., Rockville, MD, USA; 2Armed Forces Res. Inst. of Med. Sci., Bangkok, Thailand; 3Vaccine Trial Ctr., Bangkok, Thailand; 4Aventis-Pasteur, Paris, France; 5VaxGen, Inc., Brisbane, CA; and 6Thai AIDS Vaccine Evaluation Grp., Thailand, USA, and France
317 rMamu-IL-12 Conditioning during Acute SIVmac251 Infection Leads to Decreased Viral Loads and Prolonged Survival
A. A. Ansari*, A. E. Mayne, J. B. Sundstrom, P. Bostik, B. Grimm, and F. Villinger
Emory Univ. Sch. of Med., Atlanta, GA, USA
318 Determination by DNA-Delivered HIV Antigens of the Induction of Humoral or Cellular Immunity and Modulation by Genetic Adjuvants
A. Moore*, W. Kong, B. Chakrabarti, and G. J. Nabel
NIAID, NIH, Bethesda, MD, USA and Oxford Univ., UK
319 Detection of Mucosal Antibodies in HIV-Infected Individuals
P. Wright*, P. Kozlowski, E. Sannella, G. Rybczyk, P. Goepfert, H. Staats , T. VanCott , D. Trabattoni, and J. Mestecky
NIAID HIV Vaccine Trials Network
320 Characterization of Live Cell Antigen Acquisition by Dendritic Cells: Implications for Expanding and Regulating Immune Responses
L. A. Harshyne*, S. C. Watkins, A. Gambotto, and S. M. Barratt-Boyes
Graduate Sch. of Publ. Hlth., Univ. of Pittsburgh, PA, USA